Omarigliptin 13C6

[13C6]-Omarigliptin is a stable isotope-labeled form of the diabetes medication Omarigliptin. It is used in pharmacokinetic and pharmacodynamic studies to determine the metabolism, distribution, and excretion of the drug in the body. Omarigliptin is an inhibitor of dipeptidyl peptidase-4 (DPP-4), an enzyme that breaks down incretin hormones. By inhibiting DPP-4, Omarigliptin increases incretin levels, leading to increased insulin secretion and lower blood glucose levels in patients with type 2 diabetes. [13C6]-Omarigliptin is chemically identical to the non-labeled Omarigliptin, with the exception that six carbon atoms in the molecule are replaced with the stable isotope carbon-13. The stable isotope label allows for precise tracking of the drug in the body, as it can be distinguished from the naturally occurring carbon-12. This information can be used to optimize dosing regimens and improve the safety and efficacy of the drug. [13C6]-Omarigliptin is typically administered orally, and its pharmacokinetic properties are similar to those of non-labeled Omarigliptin. It is eliminated primarily through renal excretion, with a half-life of approximately 20 hours. Overall, [13C6]-Omarigliptin is a valuable tool for researchers studying the pharmacology of Omarigliptin and other DPP-4 inhibitors, and may ultimately lead to improved treatments for type 2 diabetes.